These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12455152)

  • 21. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis.
    Mancia G; Facchetti R; Parati G; Zanchetti A
    Circulation; 2012 Jul; 126(5):569-78. PubMed ID: 22761453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Data collection and statistical analyses in ELSA. European Lacidipine Study on Atherosclerosis.
    Hennig M; Neiss A
    Blood Press Suppl; 1996; 4():24-9. PubMed ID: 8973779
    [No Abstract]   [Full Text] [Related]  

  • 23. Baseline reproducibility of B-mode ultrasonic measurement of carotid artery intima-media thickness: the European Lacidipine Study on Atherosclerosis (ELSA).
    Tang R; Hennig M; Thomasson B; Scherz R; Ravinetto R; Catalini R; Rubba P; Zanchetti A; Bond MG
    J Hypertens; 2000 Feb; 18(2):197-201. PubMed ID: 10694188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcium, calcium antagonists and experimental atherosclerosis.
    Paoletti R; Corsini A; Soma MR; Bernini F
    Blood Press Suppl; 1996; 4():12-5. PubMed ID: 8973776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety aspects of treatment with lacidipine--a slow-onset, long-acting calcium antagonist.
    Lindholm LH; Tcherdakoff P; Zanchetti A
    Blood Press; 1996 Jul; 5(4):241-9. PubMed ID: 8809376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA).
    Giannattasio C; Failla M; Hennig M; Hollweck R; Laurent S; Mallion JM; Reid J; Safar M; Bond G; Zanchetti A; Mancia G
    J Hypertens; 2005 Mar; 23(3):557-62. PubMed ID: 15716697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cardiac and vascular effects of lacidipine.
    Agabiti-Rosei E
    J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S1-5. PubMed ID: 8852537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of carotid atherosclerosis in hypertension: preliminary baseline data from the European Lacidipine Study on Atheroscelerosis (ELSA).
    Zanchetti A
    Blood Press Suppl; 1996; 4():30-5. PubMed ID: 8973780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of lacidipine on experimental models of atherosclerosis.
    Bernini F; Corsini A; Raiteri M; Soma MR; Paoletti R
    J Hypertens Suppl; 1993 Mar; 11(1):S61-6. PubMed ID: 8483025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical position of lacidipine, a new dihydropyridine calcium antagonist, in the treatment of hypertension.
    Leonetti G
    J Cardiovasc Pharmacol; 1991; 18 Suppl 11():S18-21. PubMed ID: 1725445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [ELSA Studies studies progression of atherosclerosis. Calcium antagonist arrests the process more than a beta-blocker].
    Einecke D
    MMW Fortschr Med; 2001 Jul; 143(26-27):6. PubMed ID: 11481923
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety profile of lacidipine: a review of clinical data.
    Endersby CA; Brown EG; Perelman MS
    J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S45-7. PubMed ID: 1726006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lacidipine has antiatherosclerotic effects independent of its actions on lipid metabolism and blood pressure.
    Anacak GY; Ustünes L; Dilsiz OY; Ergul A
    Vascul Pharmacol; 2010; 53(5-6):193-9. PubMed ID: 20709189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of lacidipine on cholesterol esterification: in vivo and in vitro studies.
    Bernini F; Canavesi M; Bernardini E; Scurati N; Bellosta S; Fumagalli R
    Br J Pharmacol; 1997 Nov; 122(6):1209-15. PubMed ID: 9401788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct antiatherogenic activity of isradipine and lacidipine on neointimal lesions induced by perivascular manipulation in rabbits.
    Donetti E; Fumagalli R; Paoletti R; Soma MR
    Pharmacol Res; 1997 May; 35(5):417-22. PubMed ID: 9299204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The molecular basis for lacidipine's unique pharmacokinetics: optimal hydrophobicity results in membrane interactions that may facilitate the treatment of atherosclerosis.
    Herbette LG; Mason PE; Gaviraghi G; Tulenko TN; Mason RP
    J Cardiovasc Pharmacol; 1994; 23 Suppl 5():S16-25. PubMed ID: 7609501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radial artery compliance in essential hypertension: effects of antihypertensive therapy with lacidipine.
    Trazzi S; Santucciu C; Mancia G
    J Hypertens Suppl; 1993 Dec; 11(6):S17-20. PubMed ID: 8169377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lacidipine improves endothelial repair capacity of endothelial progenitor cells from patients with essential hypertension.
    Liu X; Zhang GX; Zhang XY; Xia WH; Yang Z; Su C; Qiu YX; Xu SY; Zhan H; Tao J
    Int J Cardiol; 2013 Oct; 168(4):3317-26. PubMed ID: 23642821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcium channel blocker inhibits Western-type diet-evoked atherosclerosis development in ApoE-deficient mice.
    Kyselovic J; Martinka P; Batova Z; Gazova A; Godfraind T
    J Pharmacol Exp Ther; 2005 Oct; 315(1):320-8. PubMed ID: 16020630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lercanidipine : a review of its efficacy in the management of hypertension.
    Bang LM; Chapman TM; Goa KL
    Drugs; 2003; 63(22):2449-72. PubMed ID: 14609358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.